Skip to main content
Premium Trial:

Request an Annual Quote

Cellumen to Develop Drug Toxicity Biomarkers for Mitsubishi Tanabe

NEW YORK (GenomeWeb News) – Cellumen said today that it will help Mitsubishi Tanabe Pharma to develop biomarker panels that could be used to help the company identify drug toxicity early in the drug development process.
Pittsburgh-based Cellumen offers the CellCiphr CSB Toxicity Profiling Service, which is aimed at identifying toxic compounds in late primary screening through the early pre-clinical phases of drug development. The company said the service can help companies find problematic compounds before beginning the “expensive pre-clinical testing where the pharmaceutical industry is losing millions of dollars from drugs that do not meet the FDA's safety requirements.”
The CellCiphr service provides an index of safety risks for compounds that can be used to help scientists predict potential rodent or human toxicity, the company said.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.